Click on the article title to read more.

Voordes G, Davison B, Biegus J, Edwards C, Damman K, ter Maaten J, et al. Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure: data from STRONG-HF. Eur J Heart Fail 2024; 26:1480–1492. https://doi.org/10.1002/ejhf.3336 The middle initials of Geert Voordes and Jozine ter Maaten were previously missing but

The aim of this study was to describe the prognostic importance of left ventricular ejection fraction (LVEF) versus right ventricular (RV) dilatation and dysfunction in patients with heart failure (HF) from countries of different income levels.

Introduction Heart failure with preserved ejection fraction (HFpEF) accounts for half of the hospitalization for heart failure (HF) worldwide, and the prevalence is expected to increase along with population aging and increasing burden of cardio-kidney-metabolic disorders.1 Treatment options for chronic HFpEF have expanded in recent years.2 Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are now

AimsPatients with a reduced left ventricular ejection fraction (LVEF) following an acute myocardial infarction (MI) are considered to be at risk of progressive adverse cardiac remodelling which can lead to the development of heart failure and death. The early addition of a sodium–glucose cotransporter 2 (SGLT2) inhibitor to standard treatment may delay or prevent progressive adverse remodelling in

Worldwide, valvular heart disease (VHD) is a common cause of hospitalization for acute heart failure. In acute heart failure caused by VHD, symptoms result from rapid haemodynamic changes and subsequent decline in cardiac function, and if left untreated, leads to acute decompensation and cardiogenic shock. Current evidence remains scarce and recommendations regarding the management of acute heart failure

Click on the article title to read more.

AimsDiuretic resistance (DR) in heart failure (HF) is associated with worse outcomes. Furoscix®, a self‐administered subcutaneous (sc) furosemide injection administered via on‐body infusor, is approved for HF congestion relief. However, its efficacy in patients with DR post‐HF hospitalization remains unknown.Methods and resultsIn this open‐label pilot randomized controlled trial, 70 participants were

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Gene therapy has recently become a reality in the treatment of cardiovascular diseases. Strategies to modulate gene expression using antisense oligonucleotides or small interfering RNA are proving to be safe and effective in the clinic. Adeno‐associated viral vector‐based gene delivery and CRISPR‐Cas9‐based genome editing have emerged as efficient strategies for gene delivery and repair in humans.

Introduction Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive disease that results from the accumulation of transthyretin (TTR) fibrils in the extracellular space of the myocardium, leading to heart failure.1 The pathogenesis of ATTR-CA results from a reduction in cardiac compliance due to amyloid fibril deposition, but recent observations suggest that soluble TTR intermediate oligomers

Since 2019, coronavirus disease 2019 (COVID-19) has affected millions of individuals worldwide, leading to multiple deaths and numerous long-term multiorgan sequelae. In patients with COVID-19, cardiovascular diseases, including heart failure (HF), are common and associated with an increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections1 and high mortality rates.2

Click on the article title to read more.

Click on the article title to read more.

Both American and European heart failure (HF) guidelines currently recommend initiation and optimization of guideline-directed medical therapy (GDMT), which is composed of renin–angiotensin system (RAS) inhibitors, β-blocker, mineralocorticoid receptor antagonist (MRA), and sodium–glucose cotransporter 2 (SGLT2) inhibitor, during the hospitalization for acute HF (AHF).1-3 In previous clinical trials

Timely referrals for transplantation and left ventricular assist device (LVAD) play a key role in favourable outcomes in patients with advanced heart failure (HF). Cardiovascular mortality, driven by sudden cardiac death, is the main reason for dying while waiting for heart transplantation (HTx). The purpose of the Preventive Catheter Ablation for ventricular arrhythmiaS in patients with end-sTage

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Diuretics play a central role in the management of patients with heart failure. In fact, they are used to achieve and maintain euvolaemia through adequate fluid balance. The effects, clinical benefits and implications of diuretic therapy are well established. However, little is known about the inconveniences posed to patients by diuretics and the adaptations adopted by them to counteract these challenges

Table 1 in the abstract “Length of hospital stay, re-hospitalization rates and comorbidities in patients with worsening heart failure. Data from 3 large cohort studies in the US, Germany and Japan” by A. Alexander Michel et al. has been updated as follows. Characteristics Germany n = 47,003 US n = 75,140 Japan n = 9,091 Mean age (SD), years 78.91 (10.02) 74.24 (10.88) 77.55 (10.02) Female, n (%) 23

Click on the article title to read more.

Click on the article title to read more.

AimsData from US have shown a reversal in the improvement of heart failure (HF)‐related mortality over the last ~10 years. It is unknown whether these trends generalize to European universal healthcare systems. We assessed temporal trends in (i) HF‐related mortality in the overall national population; and (ii) all‐cause mortality following an incident HF diagnosis, overall and stratified by ejection

Concerns exist that intravenous (IV) iron might increase the risk of infections. The IRONMAN trial provided an opportunity to investigate whether giving IV ferric derisomaltose (FDI) to patients with heart failure and iron deficiency alters the rate of hospitalization or death due to infections.

AimsClinical practice guidelines are commonly written by professional societies in high‐income countries (HIC) with limited anticipation of implementation obstacles in other environments. We used heart failure (HF) guidelines as a paradigm to examine this concern, by conducting a survey to understand clinicians' ability to implement HF guidelines and their perceptions of the current HF guideline applicability

Click on the article title to read more.